We have made great strides in treating many life-threatening diseases, but treatment for ALS (Lou Gehrig’s disease) has lagged behind. Unfortunately, this rare but devastating disease is fast-acting once diagnosed and affords little opportunity for study.
Families are often left scrambling to adapt and have little time to advocate for federal policy changes. Yet I, and many of my colleagues, have had the opportunity to get to know victims and their families, and it’s up to us to advocate on their behalf.
Fortunately, there are opportunities to make a difference.